-
1
-
-
84935479791
-
-
US Food and Drug Administration,January 16,Accessed 4 December 2014
-
US Food and Drug Administration. January 16, 2013 Approval Letter-Flublok. Available at: http://www.fda.gov/BiologicsBloodVaccines/ Vaccines/ApprovedProducts/ucm410628.htm. Accessed 4 December 2014.
-
(2013)
Approval Letter-Flublok
-
-
-
2
-
-
84900546305
-
Prevention and control of seasonal influenza with vaccines: Recommendations of the advisory committee on immunization practices-united states, 2013-2014
-
Accessed 4 December 2014
-
Grohskopf LA, Shay DK, Shimabukuro TT, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices-United States, 2013-2014. MMWR Recomm Rep 2013; 62(RR-07):1-43. Available at: http:// www.cdc.gov/mmwr/preview/mmwrhtml/rr6207a1.htm. Accessed 4 December 2014.
-
(2013)
MMWR Recomm Rep
, vol.62
, Issue.7 RR
, pp. 1-43
-
-
Grohskopf, L.A.1
Shay, D.K.2
Shimabukuro, T.T.3
-
3
-
-
0038341614
-
Surveillance for safety after immunization: Vaccine adverse event reporting system (vaers)-united states, 1991-2001
-
Zhou W, Pool V, Iskander JK, et al. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)-United States, 1991-2001. MMWR Surveill Summ 2003; 52:1-24.
-
(2003)
MMWR Surveill Summ
, vol.52
, pp. 1-24
-
-
Zhou, W.1
Pool, V.2
Iskander, J.K.3
-
4
-
-
1942484441
-
Understanding vaccine safety information from the vaccine adverse event reporting system
-
Varricchio F, Iskander J, Destefano F, et al. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J 2004; 23:287-94.
-
(2004)
Pediatr Infect Dis J
, vol.23
, pp. 287-294
-
-
Varricchio, F.1
Iskander, J.2
Destefano, F.3
-
5
-
-
4544251856
-
The role of the vaccine adverse event reporting system (VAERS) in monitoring vaccine safety
-
Iskander JK, Miller ER, Chen RT. The role of the Vaccine Adverse Event Reporting System (VAERS) in monitoring vaccine safety. Pediatr Ann 2004; 33:599-606.
-
(2004)
Pediatr Ann
, vol.33
, pp. 599-606
-
-
Iskander, J.K.1
Miller, E.R.2
Chen, R.T.3
-
6
-
-
84900427648
-
-
Postmarketing reporting of adverse experiences,21 CFR 600.80. Revised as of April 1
-
Postmarketing reporting of adverse experiences. Code of Federal Regulations. 21 CFR 600.80. Revised as of April 1, 2014.
-
(2014)
Code of Federal Regulations
-
-
-
7
-
-
34447313673
-
Anaphylaxis: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data
-
Ruggeberg JU, Gold MS, Bayas JM, et al. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine 2007; 25:5675-84.
-
(2007)
Vaccine
, vol.25
, pp. 5675-5684
-
-
Ruggeberg, J.U.1
Gold, M.S.2
Bayas, J.M.3
-
9
-
-
0036300732
-
Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's Spontaneous Reports database
-
Szarfman A, Machado SG, O'Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's Spontaneous Reports database. Drug Safety 2002; 25:381-92.
-
(2002)
Drug Safety
, vol.25
, pp. 381-392
-
-
Szarfman, A.1
Machado, S.G.2
O'neill, R.T.3
-
10
-
-
84935491774
-
-
US Food and Drug Administration,Accessed 4 December 2014
-
US Food and Drug Administration . Package Insert-Flublok. Available at: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ ApprovedProducts/UCM336020.pdf. Accessed 4 December 2014.
-
Package Insert-Flublok
-
-
-
11
-
-
84898047827
-
Absence of associations between influenza vaccines and increased risks of seizures, Guillain-Barré syndrome, encephalitis, or anaphylaxis in the 2012-2013 season
-
Kawai AT, Li L, Kulldorff M, et al. Absence of associations between influenza vaccines and increased risks of seizures, Guillain-Barré syndrome, encephalitis, or anaphylaxis in the 2012-2013 season. Pharmacoepidemiol Drug Saf 2014; 23:548-53.
-
(2014)
Pharmacoepidemiol Drug Saf
, vol.23
, pp. 548-553
-
-
Kawai, A.T.1
Li, L.2
Kulldorff, M.3
-
12
-
-
84887606858
-
Evaluating the safety of influenza vaccine using a claims-based health system
-
McCarthy NL, Gee J, Lin ND, et al. Evaluating the safety of influenza vaccine using a claims-based health system. Vaccine 2013; 31:5975-82.
-
(2013)
Vaccine
, vol.31
, pp. 5975-5982
-
-
McCarthy, N.L.1
Gee, J.2
Lin, N.D.3
-
13
-
-
73949155371
-
Near real-time surveillance for influenza vaccine safety: Proof-of-concept in the vaccine safety datalink project
-
Greene SK, Kulldorff M, Lewis EM, et al. Near real-time surveillance for influenza vaccine safety: proof-of-concept in the Vaccine Safety Datalink Project. Am J Epidemiol 2010; 171:177-88.
-
(2010)
Am J Epidemiol
, vol.171
, pp. 177-188
-
-
Greene, S.K.1
Kulldorff, M.2
Lewis, E.M.3
-
14
-
-
84893616243
-
Intussusception risk after rotavirus vaccination in U.S. Infants
-
Yih WK, Lieu TA, Kulldorff M, et al. Intussusception risk after rotavirus vaccination in U.S. infants. N Engl J Med 2014; 370:503-12.
-
(2014)
N Engl J Med
, vol.370
, pp. 503-512
-
-
Yih, W.K.1
Lieu, T.A.2
Kulldorff, M.3
-
15
-
-
78149349684
-
-
US Food and Drug Administration,Accessed 4 December 2014
-
US Food and Drug Administration. FDA's Sentinel Initiative. Available at: http://www.fda.gov/Safety/FDAsSentinelinitiative/ucm2007250.htm. Accessed 4 December 2014.
-
FDA's Sentinel Initiative
-
-
-
16
-
-
84935435014
-
-
Centers for Disease Control and Prevention,Accessed 4 December 2014
-
Centers for Disease Control and Prevention. Clinical Immunization Safety Assessment (CISA) Project. Available at: http://www.cdc.gov/ vaccinesafety/Activities/cisa.html. Accessed 4 December 2014.
-
Clinical Immunization Safety Assessment (CISA) Project
-
-
|